Alternative agents used in ADHD;"Alternative" pharmakologische therapien bei ADHS

Psychopharmakotherapie

Volumn 14, Issue 6, 2007, Pages 229-236

  Häßler, Frank ^a   Dück, Alexander ^a   Reis, Olaf ^a   Buchmann, Johannes ^a  

^a Klinik für Psychiatrie Neurologie Psychosomatik und Psychotherapie im Kindes und Jugendalter   (Germany)

Author keywords

ADHD; Alternative drugs and substances

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CLONIDINE; DESIPRAMINE; DOPAMINE; GUANFACINE; IMIPRAMINE; LEVODOPA; MAGNESIUM; METHYLPHENIDATE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NORADRENALIN; PHENOTHIAZINE; PHENYTOIN; PLACEBO; POLYUNSATURATED FATTY ACID; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZINC;

ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CLINICAL TRIAL; DRUG EFFICACY; EPILEPSY; HOMEOPATHY; HUMAN; REVIEW;

EID: 36549072098     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Adler LA, Resnick S, Kunz M, Devinsky O. Open-label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacol Bull 1995;31:785-8.
2. Akhondzadeh S, Mohammadi MR, Khademi M. Zinc sulfate as adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: A double-blind and randomized trial. BMC Psychiatry 2004;4:9-14.
3. Aman MG, Mitchell EA, Turbott SH. The effects of essential fatty acid supplementation by efamol in hyperactive children. J Abnorm Child Psychol 1987;15:75-90.
4. Aman MG, De Smedt G, Derivan A, Lyons B, et al.. Risperidone disruptive behavior study group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviours in children with subaverage intelligence. Am J Psychiatry 2002;159:1337-46.
5. Antkowiak R, Rajewski A. Administration of moclobemide++ in children with attention deficit hyperactivity disorder. Psychiatr Pol 1998;32:751-7.
6. Arnold LE, Bozzolo H, Hollway J, Cook A, et al. Serum zinc correlates with parents- and teacher-rated inattention in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacology 2005;15:628-36.
7. Bandelow B, Heise CA, Banaschewski T, Rothenberger A (Hrsg.). Handbuch Psychopharmaka für das Kindes- und Jugendalter. Göttingen: Hogrefe, 2006.
8. Barrickman L, Perry P, Allen A, Kuperman S, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34:649-57.
9. Bekaroglu M, Yakup A, Yusof G, Orhan D, et al. Relationship between serum-free fatty acids and zinc and ADHD. J Child Psychol Psychiatry 1996;37:225-7.
10. Bilici M, Yildirim F, Kandil S, Bekaroglu M, et al. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:181-90.
11. Buitelaar JK, Van der Gaag RJ, Swaab-Barneveld H, Kuiper M. Pindolol and methylphenidate in children with attention deficit hyperactivity disorder. Clinical efficacy and side-effects. J Child Psychol Psychiat 1996;37:587-95.
12. Burgess JR, Stevens LJ, Zhang W, Peck L. Long-chain polyunsaturated fatty acids in children with attention deficit hyperactivity disorder. Am J Clin Nutr 2000;71:327-30.
13. Cantwell DP, Swanson J, Connor DF. Case study: adverse response to clonidine. J Am Acad Child Adolesc Psychiatry 1997;36:539-44.
14. Casat CD, Pleasants DZ, Fleet JVW. A double-blind trial of bupropion in children with attention deficit disorder. Psychopharmacol Bull 1987;23:120-2.
15. 1A-receptor agonists and subtypes of alpha-1-adrenoreceptors on rabbit aorta. Eur J Pharmacol 1993;24:141-8.
16. Chen JR, Hsu SF, Hsu CD, Hwang LH, et al. Dietary patterns and blood fatty acid composition in children with attention deficit hyperactivity disorder in Taiwan. J Nutr Biochem 2004;15:467-72.
17. Conners CK, Casat CD, Gualtieri CT, Weller E, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996;35:1314-21.
18. Connor DF. Beta blockers for aggression: A review of the pediatric experience. J Child Adolesc Psychopharmacol 1993;2:99-114.
19. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999;38:1551-9.
20. Cosgrove PVF. Risperidone added to methylphenidate in attention deficit hyperactivity disorder. Eur Neuropsychopharmacol 1996;6(Suppl 3):11-2.
21. Croonenberghs J, Fegert JM, Findling RL, De Smedt G, et al.. Risperidone in children with disruptive behavior disorders and subaverage intelligence: 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 2005;44:64-72.
22. Döpfner M. Alternative Therapien. ADHS-Report 2006;23:1-4.
23. Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention deficit hyperactivity disorder. N Engl J Med 1999;340:780-8.
24. Engelberg H. Low serum cholesterol and suicide. Lancet 1992;339:727-9.
25. Findling RL, Schwartz MA, Flannery DJ, Manos MJ. Venlafaxine in adults with attention deficit hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996;57:184-9.
26. Frei H, Everts R, von Ammon K, Kaufmann F, et al. Homeopathic treatment of children with attention deficit hyperactivity disorder: a randomised double-blind, placebo controlled cross-over trial. Eur J Pediatrics 2005;164:758-67.
27. Frei H, Everts R. von Ammon K, Kaufmann F, et al. Randomised controlled trials of homeopathy in hyperactive children: treatment procedure leads to an unconventional study design. Experience with open-label homeopathic treatment preceding the Swiss ADHD placebo controlled, randomised, double-blind, crossover trial. Homeopathy 2007;96:35-41.
28. Gittelman-Klein R, Klein DF, Katz S. Comparative effects of methylphenidate and thioridazine in hyperactive children: I. Clinical results. Arch Gen Psychiatry 1976;33:1217-31.
29. Greenberg LM, Deem MA, McMahon S. Effects of dextroamphetamine, chlorpromazine, and hydroxyzine on behavior and performance in hyperactive children. Am J Psychiatry 1972;129:532-9.
30. Greydanus D. Pharmacological treatment of attention deficit hyperactivity disorder. Indian J Pediatr 2005;72:953-60.
31. Häßler F, Buchmann J, Göhre C, Fegert JM. Hyperkinetische Störungen - Pharmakotherapeutische Alternativen zu Stimulanzien. Psychopharmakotherapie 2001;8:63-70.
32. Häßler F, Göhre C, Irmisch G. Buspiron - eine Alternative zu Stimulanzien in der Therapie hyperkinetischer Störungen. In: Lehmkuhl U (Hrsg.). Psychotherapie und Psychopharmakotherapie im Kindes- und Jugendalter. Göttingen: Vandenhoeck & Ruprecht, 2003: 100-7.
33. Häßler F, Buchmann J, Reis O. Psychopharmaka und Polypharmazie. Nervenheilkunde 2005;24:811-8.
34. Hazell PL, McDowell M, Walton J. Management of children prescribed psychostimulant medication for attention deficit hyperactivity disorder in the Hunter region of New South Wales. Med J Aust 1996;165:477-80.
35. Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 2003;42:886-94.
36. Hedges D, Reimherr FW, Rogers A, Strong R, et al. An open trial of venlafaxin in adult patients with attention hyperactivity disorder. Psychopharmacol Bull 1995;31:779-83.
37. Hibbeln JR, Linnoila M, Umhau JC, Rawlings R, et al. Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics. Biol Psychiatry 1998;44:235-42.
38. Himpel S, Banaschewski T, Heise CA, Rothenberger A. The safety of non-stimulant agents for the treatment of attention deficit hyperactivity disorder. Expert Opin Drug Saf 2005;4:311-21.
39. Huss M. Vorbereitung der Erhebung und Auswertung zur Prävalenz des Aufmerksamkeits-Defizit-Hyperaktivitäts-Syndrom (ADHS) in Deutschland im Rahmen des Kinder- und Jugend-Surveys des Robert-Koch-Instituts. Abschlussbericht an das Bundesministerium für Gesundheit und Soziale Sicherung (BMGS). Bonn: BMGS 2004.
40. Irmisch G, Wiechert P, Häßler F, Langemann I. Fatty acid patterns of serum lipids and the hypermotoric syndrome. Neurosciences 1992;18:77-80.
41. Jacobs J, Williams AL, Girard C, Njike VY, et al. Homeopathy for attention deficit hyperactivity disorder: a pilot randomized controlled trial. J Altem Complement Med 2005;11:799-806.
42. Johnston JA, Ye W, Van Brunt DL, Pohl G, et al. Decreased use of clonidine following treatment with atomoxetine in children with ADHD. J Clin Psychopharmacol 2006;26:389-95.
43. Joshi K, Lad S, Kale M, Patwardhan B, et al. Supplementation with flax oil and vitamin C improves the outcome of attention deficit hyperactivity disorder (ADHD). Prostaglandins Leukot Essent Fatty Acids 2006;74:17-21.
44. Langer DH, Rapoport JL, Brown GL, Ebert MH, et al. Behavioral aspects of carbidopa/levodopa in hyperactive boys. J Am Acad Child Adolesc Psychiatry 1982;21:10-8.
45. Malhotra S, Santosh PJ. An open clinical trial of buspirone in children with attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1998;37:364-71.
46. Mann JJ. Violence and aggression. In: Bloom FE, Kupfer DJ (eds.). Psychopharmacology: The fourth generation of progress. New York: Raven, 1995:1919-28.
47. Mattes JA, Gittelman R. A pilot trial of amantadine in hyperactive children. Paper presented at the NCDEU meeting, KEY Biscayne, Florida, 1979.
48. Mattes JA. Propranolol for adults with temper outbursts and residual attention deficit disorder. J Clin Psychopharmacol 1986;6:299-302.
49. Mitchell EA, Aman MG, Turbott SH, Manku M. Clinical characteristics and serum essential fatty acids levels in hyperactive children. Clin Pediatr 1987;26:406-11.
50. Mousin-Bosc M, Roche M, Rapin J, Bali JP. Magnesium VitB6 intake reduces central nervous system hyperexcitability in children. J Am Coll Nutr 2004;23:545-8.
51. Overtoon CC, Verbaten MN, Kemner C, Kenemans JL, et al. Effects of methylphenidate, desipramine, and L-dopa on attention and inhibition in children with attention deficit hyperactivity disorder. Behav Brain Res 2003;145:7-15.
52. Popper CW. Combining methylphenidate and clonidine: pharmacological questions and news reports about sudden death. J Child Adolesc Psychopharm 1995;5:157-66.
53. Popper CW. Pharmacologic alternatives to psychostimulants for the treatment of attention deficit hyperactivity disorder. Child Adolesc Psychiatric Clin North Am 2000;9:605-46.
54. Richardson AJ, Puri BK. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:233-9.
55. Richardson AJ, Montgomery P. The Oxford-Durham study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 2005;115:1360-6.
56. Rote Liste. Frankfurt/Main: Rote Liste Service GmbH, 2006.
57. Sobanski E, Alm B. Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörung (ADHS) im Erwachsenenalter. Nervenarzt 2004;75:697-716.
58. Solhkhah R, Wilens TE, Daly J, Prince JB, et al. For the treatment of substance-abusing outpatient adolescents with attention deficit hyperactivity disorder and mood disorders. J Child Adolesc Psychopharmacol 2005;15:777-86.
59. Starobrat-Hermelin B, Kozielec T. The effects of magnesium physiological supplementation on hyperactivity in children with attention deficit hyperactivity disorder (ADHD). Positive response to magnesium oral loading test. Mag Res 1997;10:149-56.
60. Stevens LJ, Zentall SS, Deck JL, Abate ML, et al. Essential fatty acid metabolism in boys with attention deficit hyperactivity disorder. Am J Clin Nutr 1995;62:761-8.
61. Stevens L, Zhang W, Peck L, Kuczek T, et al.. EFA supplementation in children with attention, hyperactivity, and other disruptive behaviours. Lipids 2003;38:1007-21.
62. Trott GE, Menzel M, Friese HJ, Nissen G. Wirksamkeit und Verträglichkeit des selektiven MAO-A-Inhibitors Moclobemid bei Kindern mit hyperkinetischem Syndrom. Z Kinder Jugendpsychiatr Psychother 1991;19:248-53.
63. Voigt RG, Llorente AM, Jensen CL, Fraley JK, et al. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention deficit hyperactivity disorder. J Pediatr 2001;139:189-96.
64. Vorstand der Bundesärztekammer. Stellungnahme zur "Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS)". Dtsch Ärztebl 2005;102:2562-8.
65. Ward NI. Assessment of chemical factors in relation to child hyperactivity. J Nutr Environ Med (Abington) 1997;7:333-42.
66. Werry J, Aman M, Lampen E. Haloperidol and methylphenidate in hyperactive children. Acta Paedopsychiatr 1976;42:26-40.
67. Wilens TE, Spencer TJ, Biederman J, Girard K, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158:282-8.
68. Wilens TE, Prince JB, Spencer T, Van Patten SL, et al. An open trial of bupropion for the treatment of adults with attention deficit hyperactivity disorder and bipolar disorder. Biol Psychiatry 2003;54:9-16.
69. Wilens T. Mechanism of action of agents used in attention deficit hyperactivity disorder. J Clin Psychiatry 2006;67(Suppl 8):32-7.
70. Young GS, Maharaj NJ, Conquer JA. Blood phospholipids fatty acid analysis of adults with and without attention deficit hyperactivity disorder. Lipids 2004;39:117-23.
71. Young G, Conquer J. Omega-3-fatty acids and neuropsychiatric disorders. Reprod Nutr Dev 2005;45:1-28.